GDPD3 and chronic myelogenous leukemia, BCR-ABL1 positive: However, this enhanced disease-initiating capacity had attenuated by six months post-Dox withdrawal such that more Gdpd3−/− tet-CML mice survived longer than did Gdpd3+/+ tet-CML mice.